Kahira Pharmaceuticals logs EGP 38.8M profit in 3 months
Updated 11/6/2022 12:49:17 PM
Arab Finance: Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 4.8% year-on-year (YoY) increase in net profit after tax for the first quarter (Q1) of fiscal year (FY) 2022/2023, according to the unaudited financial statement filed to the Egyptian Exchange (EGX) on November 6th.
The company recorded a net profit after tax of EGP 38.796 million in Q1 FY 2022/2023, compared to EGP 37.004 million in the FY-ago quarter.
Sales fell by 2.9% to EGP 251.129 million in the July-September period from EGP 258.556 million in the same period of FY 2022/2021.
Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.
